Short-term therapy with R568 ameliorated secondary hyperparathyroidism but does not prevent aortic valve calcification in uremic rats

Renal failure associated aortic valve calcification (AVC) is the result of hyperphosphatemia and hyperparathyroidism. Calcimimetics is an effective tool for management of secondary hyperparathyroidism. Our goal was to evaluate the effect of the medical intervention with calcimimetic R568 on the AVC...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in Nephrology (Online) 2024-08, Vol.4, p.1385705
Main Authors: Abu-Snieneh, Asmahan, Gurt, Irina, Abedat, Suzan, Lotan, Chaim, Glikson, Michael, Shuvy, Mony
Format: Article
Language:English
Subjects:
animal model
aortic valve calcification
chronic kidney disease
Nephrology
phosphate
R568
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal failure associated aortic valve calcification (AVC) is the result of hyperphosphatemia and hyperparathyroidism. Calcimimetics is an effective tool for management of secondary hyperparathyroidism. Our goal was to evaluate the effect of the medical intervention with calcimimetic R568 on the AVC process. The experimental design consisted of administering a uremia-inducing phosphate-enriched diet to rats for six weeks. Rats received a daily R568 injection at different times. Biochemical analysis demonstrated increased urea (34.72 ± 3.57 . 5.18 ± 0.15 mmol/L,
ISSN:2813-0626
2813-0626
DOI:10.3389/fneph.2024.1385705